FDX104 (4% Doxycycline)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Conditions
Rash Due to Epidermal Growth Factor Receptor Inhibitors
Trial Timeline
Oct 1, 2014 → Oct 1, 2015
NCT ID
NCT02239731About FDX104 (4% Doxycycline)
FDX104 (4% Doxycycline) is a phase 2 stage product being developed by Vyne Therapeutics for Rash Due to Epidermal Growth Factor Receptor Inhibitors. The current trial status is completed. This product is registered under clinical trial identifier NCT02239731. Target conditions include Rash Due to Epidermal Growth Factor Receptor Inhibitors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02239731 | Phase 2 | Completed |
Competing Products
5 competing products in Rash Due to Epidermal Growth Factor Receptor Inhibitors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Minocycline + Clindamycin 2% in hydrocortisone 1% lotion + Erlotinib + Topical clindamycin 2%, triamcinolone acetonide 0.1% soln | Roche | Phase 2 | 52 |
| Topical Dapsone 5% Gel + oral antibiotics | Bristol Myers Squibb | Phase 3 | 76 |
| 0.25 % Miconazole Nitrate Ointment | GSK plc | Approved | 84 |
| CeraVe Baby Diaper Rash Cream + Desitin Maximum Strength Original Paste | Bausch Health | Pre-clinical | 18 |
| ATR04-484 + Vehicle | Azitra | Phase 1/2 | 33 |